Xencor, Inc. (NASDAQ:XNCR) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communications & IR Bassil Dahiyat - Co-Founder and CEO Nancy Valente - Chief Development Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Mara Goldstein - Mizuho Securities Etzer Darout - BMO Capital Markets Edward Tenthoff - Piper Sandler Brian Chang - JPMorgan Alec Stranahan - Bank of America Merrill Lynch Kaveri Pohlman - BTIG C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ _______________________________________________ Commission file number: ...

Xencor, Inc. (NASDAQ:XNCR) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communications, Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Nancy Valente - Chief Development Officer Conference Call Participants Supawat Thongthip - Mizuho Edward Tenthoff - Piper Sandler Brian Cheng - JPMorgan David Nierengarte ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ _______________________________________________ Commission file number: ...

Table of Contents` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________________ FORM 10-K __________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _________________________ ...

Xencor, Inc. (NASDAQ:XNCR) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and IR Bassil Dahiyat - President and CEO Allen Yang - Chief Medical Officer John Kuch - CFO John Desjarlais - Chief Scientific Officer Conference Call Participants Mara Goldstein - Mizuho Edward Tenthoff - Piper Sandler Dane Leone - Raymond James Etzer Darout - BMO Capital Markets David Dai - SMBC Charles Zhu - Guggenheim Partners William Maughan - Can ...

Proteins by Design® XmAb® Antibody & Cytokine Therapeutics ® Corporate Overview November 2022 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the tim ...

| --- | --- | --- | --- | --- | |--------------------|-------|-------|-------|-------| | | | | | | | Proteins by Design | | ® | | | Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; ...

Xencor Reports Second Quarter 2021 Financial Results August 4, 2021 -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--(BUSINESS WIRE)--Aug. 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights. "Xenco ...

Antibodies by Design™ XmAb® Antibody Therapeutics Corporate Overview August 2020 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and resu ...